

Supplementary Table 7 Sensitivity analyses on the primary and secondary analyses of post-treatment BP impact on various outcomes

Clinical outcome	BP level	Unadjusted analyses				Adjusted analyses*		
		Studies	SMD (95% CI)	P	Heterogeneity	Studies	OR (95% CI)	P
FFO	SBP	2	-0.21 (-0.31 to -0.10)	<0.01	$I^2=28\%$, P for Cochran Q=0.29	4	0.83 (0.78 to 0.89)	<0.01
	DBP	2	-0.02 (-0.12 to 0.08)	0.70	$I^2=28\%$, P for Cochran Q=0.30	1	0.97 (0.84 to 1.12)	0.68
FI	SBP	4	-0.21 (-0.31 to -0.11)	<0.01	$I^2=16\%$, P for Cochran Q=0.64	4	0.70 (0.56 to 0.87)	<0.01
	DBP	3	0.00 (-0.17 to 0.17)	0.99	$I^2=12\%$, P for Cochran Q=0.70	1	0.86 (0.68 to 1.09)	0.21
sICH	SBP	3	0.52 (-0.04 to 1.08)	0.07	$I^2=63\%$, P for Cochran Q=0.22	4	1.11 (1.02 to 1.22)	0.02
	DBP	3	0.22 (-0.45 to 0.88)	0.52	$I^2=73\%$, P for Cochran Q=0.10	2	1.08 (0.90 to 1.28)	0.39
Mortality	SBP	-	-	-	-	3	1.19 (0.95 to 1.51-)	0.13
	DBP	-	-	-	-	1	1.09 (0.81 to 1.47)	0.57

BP, blood pressure; SMD, standardized mean difference; CI, confidence interval; OR, odds ratio; FFO, favorable functional outcome (modified Rankin Scale [mRS] 0–1); SBP, systolic blood pressure; DBP, diastolic blood pressure; FI, functional independence (mRS 0–2); sICH, symptomatic intracranial hemorrhage.

*In the adjusted for potential confounders analyses all associations of SBP/DBP with the outcomes of interest are presented per 10 mm Hg SBP/DBP increment.